ALENQORE 70mg Tablet

What is ALENQORE 70mg

ALENQORE 70 mg contains the active ingredient alendronic acid, a nitrogen-containing bisphosphonate widely used to treat and prevent osteoporosis. It helps strengthen bones and reduce fracture risk.

• Generic name: Alendronic acid (alendronate sodium)
• Form: Oral tablet
• Strength: 70 mg
• Packaging: 4‑tablet blister pack
• Class: Bisphosphonate, antiresorptive agent :contentReference[oaicite:1]{index=1}
• Indications: Postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and prevention of fractures :contentReference[oaicite:2]{index=2}
• Benefit: Inhibits bone resorption, slows bone loss, increases bone mineral density, and reduces fracture risk

ALENQORE offers the convenience of once-weekly dosing, promoting patient adherence in long-term osteoporosis management.

How to use ALENQORE 70mg

Proper administration is essential to maximize absorption and minimize gastrointestinal side effects.

• Timing: Take first thing in the morning, at least 30 minutes before food, beverages (other than water), or other medications :contentReference[oaicite:3]{index=3}.
• Instructions: Swallow tablet whole with a full glass (240 mL) of plain water—not mineral water, coffee, juice, or tea :contentReference[oaicite:4]{index=4}.
• Post-dose posture: Remain upright (standing or sitting) for at least 30 minutes to reduce esophageal irritation :contentReference[oaicite:5]{index=5}.
• Weekly scheduling: Take one tablet once weekly on the same day each week—missed doses can be taken the next morning, but do not double dose :contentReference[oaicite:6]{index=6}.
• Contraindications: Avoid bedtime dosing; do not lie down within 30 minutes.
• Supplementation: Ensure sufficient calcium and vitamin D intake—dietary or supplemental—unless contraindicated :contentReference[oaicite:7]{index=7}.

Regular medical follow-up, including bone density and blood tests, help assess treatment effectiveness and safety.

Mode of Action ALENQORE 70mg

Alendronic acid works by selectively targeting and inhibiting osteoclasts—the cells responsible for bone resorption.

• Bone binding: After absorption, alendronate binds to hydroxyapatite in bone and is taken up by active osteoclasts :contentReference[oaicite:8]{index=8}.
• Enzyme inhibition: It inhibits farnesyl diphosphate synthase in the mevalonate pathway, disrupting prenylation of GTPases needed for osteoclast function :contentReference[oaicite:9]{index=9}.
• Osteoclast apoptosis: Disrupted cell signalling leads to osteoclast apoptosis, reducing bone resorption.
• Net effect: Reduced bone turnover allows osteoblasts to build bone, increasing bone mineral density and reducing fractures :contentReference[oaicite:10]{index=10}.
• Long skeletal retention: It remains bound in bone for years, providing sustained effect despite weekly dosing :contentReference[oaicite:11]{index=11}.

ALENQORE 70mg Interactions ALENQORE 70mg

Alendronate absorption can be reduced by cation-containing products; GI effects may worsen with NSAIDs.

• Calcium, magnesium, iron supplements and antacids: Reduce absorption; take at least 30 minutes after alendronate :contentReference[oaicite:12]{index=12}.
• NSAIDs (e.g., ibuprofen, naproxen): Increase risk of esophageal and gastric irritation :contentReference[oaicite:13]{index=13}.
• Aspirin: May exacerbate GI side effects :contentReference[oaicite:14]{index=14}.
• Polyvalent cations: Zinc, aluminum hydroxide interfere with absorption; space dosing by ≥30 minutes :contentReference[oaicite:15]{index=15}.
• Thiazide diuretics: May increase hypocalcemia risk.
• No major CYP drug interactions noted.

Disclose all medications and supplements to your provider to optimize treatment and minimize interactions.

Dosage of ALENQORE 70mg

The standard dosing regimen is simple and consistent:

• Adults with osteoporosis: 70 mg orally once weekly :contentReference[oaicite:16]{index=16}.
• Prevention in postmenopausal women: Same 70 mg weekly dose :contentReference[oaicite:17]{index=17}.
• Glucocorticoid-induced osteoporosis: Typically 5–10 mg daily, but weekly regimens can apply.
• Paget’s disease: Usually 40 mg daily for 6 months (not the 70 mg dose).
• Renal impairment: Avoid if creatinine clearance is <35 mL/min :contentReference[oaicite:18]{index=18}.
• Elderly: No dose adjustment needed, but monitor bone and kidney function.

Never exceed one tablet weekly; if missed, take the next morning and resume weekly schedule. Avoid doubling up doses.

Possible side effects of ALENQORE 70mg

While generally well tolerated, alendronate can cause GI irritation and rare serious side effects.

• Common (1–10%): Gastrointestinal upset (nausea, abdominal pain, heartburn, acid reflux, constipation, diarrhea) :contentReference[oaicite:19]{index=19}.
• Musculoskeletal pain: Bone, joint, or muscle pain—even severe cases—may occur :contentReference[oaicite:20]{index=20}.
• Esophageal effects: Esophagitis, ulcers, stricture if not taken upright :contentReference[oaicite:21]{index=21}.
• Serious rare effects:
  • Osteonecrosis of the jaw, especially after dental work (~<1/1,000) :contentReference[oaicite:22]{index=22}.
  • Atypical femur fractures with long-term use :contentReference[oaicite:23]{index=23}.
  • Hypocalcemia—particularly if baseline levels are low :contentReference[oaicite:24]{index=24}.
  • Severe esophageal damage—bleeding, perforation :contentReference[oaicite:25]{index=25}.
  • Rare eye inflammation (uveitis, scleritis) :contentReference[oaicite:26]{index=26}.

If serious symptoms like jaw pain, thigh pain, difficulty swallowing, chest pain, or allergic reactions occur, contact a healthcare provider immediately.

ALENQORE 70mg Contraindications ALENQORE 70mg

Before starting ALENQORE, certain conditions must be ruled out:

• Esophageal abnormalities: Stricture or achalasia that delay gastric emptying :contentReference[oaicite:27]{index=27}.
• Inability to remain upright: Must sit or stand for at least 30 minutes post-dose :contentReference[oaicite:28]{index=28}.
• Hypocalcemia: Low blood calcium must be corrected before treatment :contentReference[oaicite:29]{index=29}.
• Renal impairment: Avoid if creatinine clearance <35 mL/min :contentReference[oaicite:30]{index=30}.
• Hypersensitivity: Known allergy to alendronate or any tablet component :contentReference[oaicite:31]{index=31}.
• Pediatric use: Not recommended for children under 18 years :contentReference[oaicite:32]{index=32}.

Thorough patient evaluation is essential to ensure efficacy and reduce risk.

Storage of ALENQORE 70mg

Proper storage ensures the medication remains effective throughout its shelf life.

• Temperature: Store at room temperature (15–30 °C) in a dry place away from heat and moisture :contentReference[oaicite:33]{index=33}.
• Packaging: Keep tablets in original blister until use to shield from humidity and light :contentReference[oaicite:34]{index=34}.
• Environment: Avoid bathrooms or other high-humidity areas.
• Child safety: Store securely out of reach of children and pets.
• Disposal: Do not flush tablets. Dispose of expired or unused medication per local pharmacy or waste guidelines :contentReference[oaicite:35]{index=35}.
• Expiry awareness: Do not use past the printed expiry date.

Following storage recommendations preserves potency and maintains patient safety.